A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
|Videos|December 9, 2019
Frequent bathing could help in pediatric atopic dermatitis
Author(s)Bobby Lazzara, M.D.
Advertisement
Published in the Journal of Allergy and Clinical Immunology in Practice, a randomized, single-blind, crossover-controlled trial comparing twice daily soaking baths followed by application of an occlusive moisturizer vs. twice weekly soaking baths in a small pediatric population with atopic dermatitis.
The results: The twice daily bathing method significantly decreased SCORAD compared with twice weekly as an acute treatment intervention with a 30% improvement in SCORAD.
Caregiver assessment was also significantly improved in the twice daily group.
What are you going to recommend to your patients?
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5